




Instance: composition-en-83d27b2c0c103aeb8cf9aa2b77c5f35f
InstanceOf: CompositionUvEpi
Title: "Composition for halaven Package Leaflet"
Description:  "Composition for halaven Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp83d27b2c0c103aeb8cf9aa2b77c5f35f)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - halaven"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol>
<li>What HALAVEN is and what it is used for  </li>
<li>What you need to know before you use HALAVEN  </li>
<li>How to use HALAVEN  </li>
<li>Possible side effects  </li>
<li>How to store HALAVEN </li>
<li>Contents of the pack and other information  </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What halaven is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What halaven is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>HALAVEN contains the active substance eribulin and is an anti-cancer medicine which works by 
stopping the growth and spread of cancer cells. </p>
<p>It is used in adults for locally advanced or metastatic breast cancer (breast cancer that has spread 
beyond the original tumour) when at least one other therapy has been tried but has lost its effect.  </p>
<p>It is also used in adults for advanced or metastatic liposarcoma (a type of cancer that arises from fat 
tissue) when previous therapy has been tried but has lost its effect. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take halaven"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take halaven"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not use HALAVEN:</p>
<ul>
<li>if you are allergic to eribulin mesilate or any of the other ingredients of this medicine (listed in 
section 6).  </li>
<li>if you are breast-feeding </li>
</ul>
<p>Warnings and precautions 
Talk to your doctor or nurse before using HALAVEN:</p>
<ul>
<li>if you have liver problems </li>
<li>if you have a fever or an infection </li>
<li>if you experience numbness, tingling, prickling sensations, sensitivity to touch or muscle 
weakness </li>
<li>if you have heart problems </li>
</ul>
<p>If any of these affects you, tell your doctor who may wish to stop treatment or reduce the dose. </p>
<p>Children and adolescents </p>
<p>Do not give this medicine to children between the ages of 0 to 18 years because it does not work. </p>
<p>Other medicines and HALAVEN 
Tell your doctor if you are using, have recently used or might use any other medicines. </p>
<p>Pregnancy, breast-feeding and fertility 
HALAVEN may cause serious birth defects and should not be used if you are pregnant unless it is 
thought clearly necessary after carefully considering all the risk to you and the baby. It may also cause 
future permanent fertility problems in men if they take it and they should discuss this with their doctor 
before starting treatment. Women of childbearing age should use effective contraception during and up 
to 3 months after treatment with HALAVEN. </p>
<p>HALAVEN must not be used during breast-feeding because of the possibility of risk to the child. </p>
<p>Driving and using machines 
HALAVEN may cause side effects such as tiredness (very common) and dizziness (common). Do not 
drive or use machines if you feel tired or dizzy. </p>
<p>HALAVEN contains ethanol (alcohol) 
This medicine contains small amounts of ethanol (alcohol), less than 100 mg in a vial. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take halaven"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take halaven"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>HALAVEN will be given to you by a qualified healthcare professional as an injection into a vein, over 
a period of 2 to 5 minutes. The dose you will receive is based on your body surface area (expressed in 
squared metres, or m2) which is calculated from your weight and height. The usual dose of 
HALAVEN is 1.23 mg/m2, but this may be adjusted by your doctor based on your blood test results or 
other factors. To ensure that the whole dose of HALAVEN is given it is recommended that a saline 
solution is flushed into the vein after HALAVEN is given. </p>
<p>How often will you be given HALAVEN? 
HALAVEN is usually given on Days 1 and 8 of every 21-day cycle. Your doctor will determine how 
many cycles of treatment you should receive. Depending on the results of your blood tests, the doctor 
may need to delay administration of the medicine until the blood tests return to normal. The doctor 
may also then decide to reduce the dose you are given. </p>
<p>If you have any further questions about the use of this medicine, ask your doctor. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.  </p>
<p>If you experience any of the following serious symptoms, stop taking HALAVEN and seek medical 
attention straightaway:</p>
<ul>
<li>Fever, with a racing heart beat, rapid shallow breathing, cold, pale, clammy or mottled skin 
and/or confusion. These may be signs of a condition called sepsis   a severe and serious 
reaction to an infection. Sepsis is uncommon (may affect up to 1 in 100 people) and can be life-
threatening and may result in death. </li>
<li>Any difficulty breathing, or swelling of your face, mouth, tongue or throat. These could be signs 
of an uncommon allergic reaction (may affect up to 1 in 100 people). </li>
<li>Serious skin rashes with blistering of the skin, mouth, eyes and genitals. These may be signs of 
a condition called Stevens-Johnson syndrome/toxic epidermal necrolysis. The frequency of this 
condition is not known but it can be life-threatening. </li>
</ul>
<p>Other side effects: </p>
<p>Very common side effects (may affect more than 1 in 10 people) are:</p>
<ul>
<li>Decrease in the number of white blood cells or red blood cells </li>
<li>Tiredness or weakness </li>
<li>Nausea, vomiting, constipation, diarrhoea </li>
<li>Numbness, tingling or prickling sensations </li>
<li>Fever </li>
<li>Loss of appetite, weight loss </li>
<li>Difficulty breathing, cough </li>
<li>Pain in the joints, muscles and back </li>
<li>Headache </li>
<li>Hair loss </li>
</ul>
<p>Common side effects (may affect up to 1 in 10 people) are:</p>
<ul>
<li>Decrease in the number of platelets (which may result in bruising or taking longer to stop 
bleeding) </li>
<li>Infection with fever, pneumonia, chills </li>
<li>Fast heart rate, flushing </li>
<li>Vertigo, dizziness </li>
<li>Increased production of tears, conjunctivitis (redness and soreness of the surface of the eye), 
nosebleed </li>
<li>Dehydration, dry mouth, cold sores, oral thrush, indigestion, heartburn, abdominal pain or 
swelling </li>
<li>Swelling of soft tissues, pains (in particular chest, back and bone pain), muscle spasm or 
weakness </li>
<li>Mouth, respiratory and urinary tract infections, painful urination  </li>
<li>Sore throat, sore or runny nose, flu-like symptoms, throat pain  </li>
<li>Liver function test abnormalities, altered level of sugar, bilirubin, phosphates, potassium, 
magnesium or calcium in the blood  </li>
<li>Inability to sleep, depression, changed sense of taste </li>
<li>Rash, itching, nail problems, dry or red skin </li>
<li>Excessive sweating (including night sweats) </li>
<li>Ringing in the ears </li>
<li>Blood clots in the lungs </li>
<li>Shingles </li>
<li>Swelling of the skin and numbness of the hands and feet </li>
</ul>
<p>Uncommon side effects (may affect up to 1 in 100 people) are:</p>
<ul>
<li>Blood clots </li>
<li>Abnormal liver function tests (hepatoxicity) </li>
<li>Kidney failure, blood or protein in the urine  </li>
<li>Widespread inflammation of the lungs which may lead to scarring </li>
<li>Inflammation of the pancreas </li>
<li>Mouth ulcers </li>
</ul>
<p>Rare side effects (may affect up to 1 in 1000 people) are:</p>
<ul>
<li>A serious disorder of blood clotting resulting in the widespread formation of blood clots and 
internal bleeding. </li>
</ul>
<p>Reporting of side effects 
If you get any side effects, talk to your doctor or nurse. This includes any possible side effects not 
listed in this leaflet. You can also report side effects directly via the national reporting system listed in 
Appendix V. By reporting side effects you can help provide more information on the safety of this 
medicine. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store halaven"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store halaven"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children.  </p>
<p>Do not use this medicine after the expiry date which is stated on the carton and the vial after EXP. The 
expiry date refers to the last day of that month. </p>
<p>This medicine does not require any special storage conditions. </p>
<p>If HALAVEN is diluted for infusion, the diluted solution should be used immediately. If not used 
immediately the diluted solution should be stored at 2- 8 C for no longer than 72 hours. </p>
<p>If HALAVEN as an undiluted solution has been transferred into a syringe, it should be stored at 15-
25 C and ambient lighting for no longer than 4 hours, or at 2- 8 C for no longer than 24 hours. </p>
<p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to 
throw away medicines you no longer use. These measures will help protect the environment. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What HALAVEN contains  </p>
<ul>
<li>The active substance is eribulin. Each 2 ml vial contains eribulin mesilate equivalent to 0.88 mg 
eribulin.  </li>
<li>The other ingredients are ethanol and water for injections, with hydrochloric acid and sodium 
hydroxide possibly present in very small amounts. </li>
</ul>
<p>What HALAVEN looks like and contents of the pack  </p>
<p>HALAVEN is a clear, colourless aqueous solution for injection provided in glass vials containing 2 ml 
of solution. Each carton contains either 1 or 6 vials. </p>
<p>Marketing Authorisation Holder 
Eisai GmbH 
Edmund-Rumpler-Stra e 3<br />
60549 Frankfurt am Main 
Germany 
e-mail: medinfo_de@eisai.net </p>
<p>Manufacturer 
Eisai GmbH 
Edmund-Rumpler-Stra e 3<br />
60549 Frankfurt am Main 
Germany </p>
<p>For any information about this medicine, please contact the local representative of the Marketing 
Authorisation Holder:  </p>
<p>Belgi /Belgique/Belgien 
Eisai SA/NV 
T l/Tel: +32 (0)800 158 Lietuva 
Ewopharma AG 
Tel: +370 5 248 73 <br />
Ewopharma AG 
Te : +359 2 962 12 Luxembourg/Luxemburg 
Eisai SA/NV 
T l/Tel: + 32 (0)800 158 (Belgique/Belgien) 
 esk  republika 
Eisai GesmbH organiza n  slo ka 
Tel.: + 420 242 485 Magyarorsz g 
Ewopharma Hungary Ltd. 
Tel: +36 1 200 46 Danmark 
Eisai AB 
Tlf: + 46 (0) 8 501 01 (Sverige) 
Malta 
Cherubino LTD 
Tel: +356 21343Deutschland 
Eisai GmbH 
Tel: + 49 (0) 69 66 58 Nederland 
Eisai B.V. 
T l/Tel: + 31 (0) 900 575 3Eesti 
Ewopharma AG 
Tel. +370 5 248 73 Norge 
Eisai AB 
Tlf: + 46 (0) 8 501 01 (Sverige) </p>
<p>Eisai Ltd. 
 : + 44 (0)208 600 1(   ) 
 sterreich 
Eisai GesmbH 
Tel: + 43 (0) 1 535 1980-0 
Espa a 
Eisai Farmac utica, S.A. 
Tel: + (34) 91 455 94 Polska 
Ewopharma AG Sp. z o.o. 
Tel.: +48 (22) 620 11 France 
Eisai SAS 
T l: + (33) 1 47 67 00 Portugal 
Eisai Farmac utica, Unipessoal Lda 
Tel: + 351 214 875 Hrvatska 
Ewopharma d.o.o. 
Tel: +385 (0) 1 6646 Rom nia<br />
Ewopharma AG<br />
Tel: +40 21 260 13 Ireland 
Eisai GmbH 
Tel: + 49 (0) 69 66 58 (Germany) 
Slovenija 
Ewopharma d.o.o. 
Tel: +386 590 848  sland 
Eisai AB 
S mi: + 46 (0)8 501 01 (Sv j ) 
Slovensk  republika 
Eisai GesmbH organiza n  slo ka 
Tel.: + 420 242 485 ( esk  republika) 
Italia 
Eisai S.r.l. 
Tel: + 39 02 5181Suomi/Finland 
Eisai AB 
Puh/Tel: + 46 (0) 8 501 01 (Ruotsi) </p>
<p>Eisai Ltd. 
 : +44 (0)208 600 1(   ) 
Sverige 
Eisai AB 
Tel: + 46 (0) 8 501 01 Latvija 
Ewopharma AG 
Tel: +371 677 04United Kingdom (Northern Ireland) 
Eisai GmbH 
Tel: + 49 (0) 69 66 58 (Germany) </p>
<p>This leaflet was last revised in  </p>
<p>Detailed information on this medicine is available on the European Medicines Agency web site: </p>         </div>"""      



Instance: composition-da-83d27b2c0c103aeb8cf9aa2b77c5f35f
InstanceOf: CompositionUvEpi
Title: "Composition for halaven Package Leaflet"
Description:  "Composition for halaven Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp83d27b2c0c103aeb8cf9aa2b77c5f35f)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - halaven"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen 
1. Virkning og anvendelse<br />
2. Det skal du vide, før du begynder at bruge HALAVEN<br />
3. Sådan skal du bruge HALAVEN<br />
4. Bivirkninger<br />
5. Opbevaring 
6. Pakningsstørrelser og yderligere oplysninger  </p>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What halaven is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What halaven is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>HALAVEN indeholder det aktive stof eribulin og er et lægemiddel mod kræft, som virker ved at 
stoppe væksten og spredningen af kræftceller. </p>
<p>HALAVEN anvendes hos voksne med lokalt fremskreden eller metastatisk brystkræft (brystkræft, 
som har spredt sig udover den oprindelige kræftknude), når mindst en anden behandling er prøvet, 
men ikke længere virker. </p>
<p>Det anvendes også hos voksne med fremskreden eller metastatisk liposarkom (en type cancer, der 
opstår fra fedtvævet), når tidligere behandling er prøvet, men ikke længere virker. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take halaven"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take halaven"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Brug ikke HALAVEN:</p>
<ul>
<li>hvis du er allergisk over for eribulinmesilat eller et af de øvrige indholdsstoffer i HALAVAN 
(angivet i punkt 6) </li>
<li>hvis du ammer </li>
</ul>
<p>Advarsler og forsigtighedsregler 
Kontakt lægen eller sygeplejersken, før du bruger HALAVEN 
- hvis du har leverproblemer 
- hvis du har feber eller en infektion 
- hvis du oplever følelsesløshed, prikkende, stikkende fornemmelser, følsomhed over for berøring 
eller muskelsvaghed 
- hvis du har hjerteproblemer </p>
<p>Hvis noget af dette påvirker dig, skal du fortælle det til lægen, som kan vælge at stoppe behandlingen 
eller nedsætte dosis. </p>
<p>Børn og unge 
Dette lægemiddel må ikke gives til børn i alderen fra 0 til 18 år, da det ikke virker. </p>
<p>Brug af anden medicin sammen med HALAVEN 
Fortæl altid lægen, hvis du bruger anden medicin, for nylig har brugt anden medicin eller planlægger 
at bruge anden medicin. </p>
<p>Graviditet, amning og frugtbarhed 
HALAVEN kan forårsage alvorlige fødselsdefekter, og bør ikke anvendes hvis du er gravid, 
medmindre det menes at være klart nødvendigt efter nøje overvejelse af alle risici for dig og barnet. 
Det kan også forårsage permanente frugtbarhedsproblemer i fremtiden hos mænd, der tager 
behandlingen, og de bør diskutere dette med deres læge, før de starter behandlingen. Kvinder i den 
fertile alder skal anvende sikker kontraception under behandlingen med HALAVEN og 3 måneder 
efter behandlingen. </p>
<p>HALAVEN må ikke anvendes under amning på grund af en mulig risiko for barnet. </p>
<p>Trafik- og arbejdssikkerhed 
HALAVEN kan forårsage bivirkninger, såsom træthed (meget almindelig) og svimmelhed 
(almindelig). Lad være med at føre motorkøretøj eller betjene maskiner, hvis du føler dig træt eller er 
svimmel. </p>
<p>HALAVEN indeholder alkohol 
Denne medicin indeholder en mindre mængde alkohol, mindre end 100 mg i et hætteglas. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take halaven"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take halaven"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Du vil få HALAVEN af kvalificeret sundhedspersonale som en injektion i en vene, i løbet af en 
periode på 2 til 5 minutter. Den dosis, du får, er baseret på din krops overfladeareal (udtrykt i 
kvadratmeter, eller m2), som beregnes ud fra din vægt og højde. Den normale dosis HALAVEN er 
1,23 mg/m2, men lægen kan justere den ud fra dine blodprøveresultater eller andre faktorer. For at 
sikre, at hele dosen af HALAVEN er givet, anbefales det, at der skylles med en saltvandsopløsning i 
venen, efter HALAVEN er indgivet. </p>
<p>Hvor ofte vil du få HALAVEN? 
HALAVEN indgives normalt på Dag 1 og 8 af hver 21-dags cyklus. Din læge vil bestemme, hvor 
mange behandlingscyklusser du skal have. Afhængigt af resultaterne af dine blodprøver kan lægen 
udsætte indgivelsen af lægemidlet, indtil blodprøverne igen er normale. Lægen kan på det tidspunkt 
også beslutte sig for at reducere din dosis. </p>
<p>Spørg lægen, hvis der er noget, du er i tvivl om. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som al anden medicin give bivirkninger, men ikke alle får bivirkninger.  </p>
<p>Hvis du oplever nogle af følgende alvorlige bivirkninger, skal du holde op med at tage HALAVEN og 
straks søge lægehjælp:</p>
<ul>
<li>Feber med en galoperende puls, hurtig overfladisk vejrtrækning, kold, bleg, klam eller spættet 
hud og/eller forvirring. Dette kan være tegn på en tilstand, der kaldes sepsis (blodforgiftning) - 
en svær og alvorlig reaktion på en infektion. Sepsis er ikke almindelig (kan forekomme hos op 
til 1 ud af 100 personer) og kan være livstruende og medføre døden.  </li>
<li>Vejrtrækningsproblemer eller hævelse af ansigt, mund, tunge eller hals. Disse kunne være tegn 
på en ikke almindelig allergisk reaktion (kan forekomme hos op til 1 ud af 100 personer). </li>
<li>Alvorligt hududslæt med vabler på huden, i munden, øjnene og kønsdelene. De kan være tegn 
på en sygdom, der kaldes Stevens-Johnsons syndrom/toksisk epidermal nekrolyse. Hyppigheden 
af denne sygdom er ikke kendt, men den kan være livstruende. </li>
</ul>
<p>Andre bivirkninger: </p>
<p>Meget almindelige bivirkninger (kan forekomme hos flere end 1 ud af 10 personer) er:</p>
<ul>
<li>Nedsat antal hvide blodlegemer eller røde blodlegemer </li>
<li>Træthed eller svaghed </li>
<li>Kvalme, opkastning, forstoppelse, diarré </li>
<li>Følelsesløshed, prikkende eller stikkende fornemmelse </li>
<li>Feber </li>
<li>Appetitløshed, vægttab </li>
<li>Vejrtrækningsbesvær, hoste </li>
<li>Smerter fra led, muskler og ryg </li>
<li>Hovedpine </li>
<li>Hårtab </li>
</ul>
<p>Almindelige bivirkninger (kan forekomme hos op til 1 ud af 10 personer) er:</p>
<ul>
<li>Nedsat antal blodplader (hvilket kan føre til blå mærker eller det kan tage længere at stoppe en 
blødning) </li>
<li>Infektion med feber, lungebetændelse kulderystelser </li>
<li>Hurtig puls, rødmen </li>
<li>Svimmelhed </li>
<li>Forøget tåreproduktion, konjunktivitis (rødmen og ømhed på øjets overflade), næseblod </li>
<li>Dehydrering, mundtørhed, forkølelsessår, svampeinfektion i munden, fordøjelsesbesvær, 
halsbrand, mavesmerter eller hævelse </li>
<li>Hævelse af bløddele, smerter (især i brystet, ryggen og knoglesmerter), muskelspasmer eller 
svaghed </li>
<li>Mund-, luftvejs- og urinvejsinfektioner, smertefuld vandladning </li>
<li>Ondt i halsen, øm eller løbende næse, influenzalignende symptomer, halssmerter </li>
<li>Unormale leverfunktionsundersøgelser, ændret niveau af sukker, bilirubin, fosfat, kalium, 
magnesium eller calcium i blodet </li>
<li>Søvnløshed, depression, ændret smagssans </li>
<li>Udslæt, kløe, negleproblemer, tør eller rød hud </li>
<li>Overdreven svedtendens (herunder nattesved) </li>
<li>Ringen for ørerne </li>
<li>Blodpropper i lungerne </li>
<li>Helvedesild </li>
<li>Hævelse af hud og følelsesløshed i hænder og fødder </li>
</ul>
<p>Ikke almindelige bivirkninger (kan forekomme hos op til 1 ud af 100 personer) er:</p>
<ul>
<li>Blodpropper </li>
<li>Unormale prøver for leverfunktionen (leverskade) </li>
<li>Nyresvigt, blod eller protein i urinen </li>
<li>Udbredt betændelse i lungerne, hvilket kan medføre ardannelse </li>
<li>Betændelse i bugspytkirtlen </li>
<li>Mundsår </li>
</ul>
<p>Sjældne bivirkninger (kan forekomme hos op til 1 ud af 1.000 personer) er:</p>
<ul>
<li>En alvorlig forstyrrelse af blodstørkningen, der fører til udbredt dannelse af blodpropper og 
indre blødninger. </li>
</ul>
<p>Indberetning af bivirkninger 
Hvis du oplever bivirkninger, bør du tale med din læge eller sygeplejersken. Dette gælder også mulige 
bivirkninger, som ikke er medtaget i denne indlægsseddel. Du eller dine pårørende kan også indberette 
bivirkninger direkte til Lægemiddelstyrelsen via det nationale rapporteringssystem anført i Appendiks 
V. Ved at indrapportere bivirkninger kan du hjælpe med at fremskaffe mere information om 
sikkerheden af dette lægemiddel. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store halaven"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store halaven"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar lægemidlet utilgængeligt for børn.  </p>
<p>Brug ikke lægemidlet efter den udløbsdato, der står på kartonen og hætteglasset efter EXP. 
Udløbsdatoen er den sidste dag i den nævnte måned. </p>
<p>Dette lægemiddel kræver ingen særlige forholdsregler vedrørende opbevaringen. </p>
<p>Hvis HALAVEN fortyndes til infusion, skal den fortyndede opløsning straks anvendes. Hvis den ikke 
straks anvendes, skal den fortyndede opløsning opbevares ved 2-8 °C i højst 72 timer. </p>
<p>Hvis HALAVEN overføres til en injektionssprøjte som en ufortyndet opløsning, skal den opbevares 
ved 15-25 °C og i det omgivende lys i højst 4 timer eller ved 2-8 °C i højst 24 timer. </p>
<p>Spørg apotekspersonalet, hvordan du skal bortskaffe medicinrester. Af hensyn til miljøet må du ikke 
smide medicinrester i afløbet, toilettet eller skraldespanden. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>HALAVEN indeholder:</p>
<ul>
<li>Aktivt stof: Eribulin. Hvert 2 ml hætteglas indeholder eribulinmesilat svarende til 0,88 mg 
eribulin. </li>
<li>Øvrige indholdsstoffer: Ethanol og vand til injektionsvæsker, muligvis med meget små 
mængder saltsyre og natriumhydroxid. </li>
</ul>
<p>Udseende og pakningsstørrelser<br />
HALAVEN er en klar, farveløs, vandig injektionsvæske, opløsning, i hætteglas indeholdende 2 ml 
injektionsvæske. Hver karton indeholder enten 1 eller 6 hætteglas. </p>
<p>Indehaver af markedsføringstilladelsen 
Eisai GmbH 
Edmund-Rumpler-Straße 3<br />
60549 Frankfurt am Main<br />
Tyskland </p>
<p>E-mail: medinfo_de@eisai.net </p>
<p>Fremstiller 
Eisai GmbH 
Edmund-Rumpler-Straße 3<br />
60549 Frankfurt am Main<br />
Tyskland </p>
<p>Hvis du ønsker yderligere oplysninger om dette lægemiddel, skal du henvende dig til den lokale 
repræsentant for indehaveren af markedsføringstilladelsen:  </p>
<p>België/Belgique/Belgien 
Eisai SA/NV 
Tél/Tel: +32 (0)800 158 Lietuva 
Ewopharma AG 
Tel: +370 5 248 73 България 
Ewopharma AG 
Teл: +359 2 962 12 Luxembourg/Luxemburg 
Eisai SA/NV 
Tél/Tel: + 32 (0)800 158 58<br />
(Belgique/Belgien) 
Česká republika 
Eisai GesmbH organizační složka 
Tel.: + 420 242 485 Magyarország 
Ewopharma Hungary Ltd. 
Tel: +36 1 200 46 Danmark 
Eisai AB 
Tlf: + 46 (0) 8 501 01 600<br />
(Sverige) 
Malta 
Cherubino LTD 
Tel: +356 21343Deutschland 
Eisai GmbH 
Tel: + 49 (0) 69 66 58 Nederland 
Eisai B.V. 
Tel: + 31 (0) 900 575 3340<br />
Eesti 
Ewopharma AG 
Tel. +370 5 248 73 Norge 
Eisai AB 
Tlf: + 46 (0) 8 501 01 (Sverige) 
Ελλάδα 
Eisai Ltd. 
Τηλ: + 44 (0)208 600 1(Ηνωµένο Βασίλειο) 
Österreich 
Eisai GesmbH 
Tel: + 43 (0) 1 535 1980-0 
España 
Eisai Farmacéutica, S.A. 
Tel: + (34) 91 455 94 Polska 
Ewopharma AG Sp. z o.o. 
Tel.: +48 (22) 620 11 France 
Eisai SAS 
Tél: + (33) 1 47 67 00 Portugal 
Eisai Farmacêutica, Unipessoal Lda 
Tel: + 351 214 875 Hrvatska 
Ewopharma d.o.o. 
Tel: +385 (0) 1 6646<br />
România<br />
Ewopharma AG<br />
Tel: +40 21 260 13 Ireland 
Eisai GmbH 
Tel: + 49 (0) 69 66 58 (Germany) 
Slovenija 
Ewopharma d.o.o. 
Tel: +386 590 848 Ísland 
Eisai AB 
Sími: + 46 (0)8 501 01 600<br />
(Svíþjóð) 
Slovenská republika 
Eisai GesmbH organizační složka 
Tel.: + 420 242 485 (Česká republika) 
Italia 
Eisai S.r.l. 
Tel: + 39 02 5181Suomi/Finland 
Eisai AB 
Puh/Tel: + 46 (0) 8 501 01 (Ruotsi) 
Κύπρος 
Eisai Ltd. 
Τηλ: +44 (0)208 600 1(Ηνωµένο Βασίλειο) 
Sverige 
Eisai AB 
Tel: + 46 (0) 8 501 01 Latvija 
Ewopharma AG 
Tel: +371 677 04United Kingdom (Northern Ireland) 
Eisai GmbH 
Tel: + 49 (0) 69 66 58 (Germany) </p>
<p>Denne indlægsseddel blev senest ændret  </p>
<p>Du kan finde yderligere oplysninger om dette lægemiddel på Det Europæiske Lægemiddelagenturs 
hjemmeside: http://www.ema.europa.eu/.  </p>         </div>"""      





                    
Instance: bundlepackageleaflet-en-83d27b2c0c103aeb8cf9aa2b77c5f35f
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for halaven Package Leaflet for language en"
Description: "ePI document Bundle for halaven Package Leaflet for language en"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-83d27b2c0c103aeb8cf9aa2b77c5f35f"
* entry[0].resource = composition-en-83d27b2c0c103aeb8cf9aa2b77c5f35f

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp83d27b2c0c103aeb8cf9aa2b77c5f35f"
* entry[=].resource = mp83d27b2c0c103aeb8cf9aa2b77c5f35f
                            
                    
Instance: bundlepackageleaflet-da-83d27b2c0c103aeb8cf9aa2b77c5f35f
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for halaven Package Leaflet for language da"
Description: "ePI document Bundle for halaven Package Leaflet for language da"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-83d27b2c0c103aeb8cf9aa2b77c5f35f"
* entry[0].resource = composition-da-83d27b2c0c103aeb8cf9aa2b77c5f35f

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp83d27b2c0c103aeb8cf9aa2b77c5f35f"
* entry[=].resource = mp83d27b2c0c103aeb8cf9aa2b77c5f35f
                            
                    



Instance: mp83d27b2c0c103aeb8cf9aa2b77c5f35f
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product HALAVEN 0.44 mg/ml solution for injection"
Description: "HALAVEN 0.44 mg/ml solution for injection"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/11/678/001-002"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"



* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"

* name
  * productName = "HALAVEN 0.44 mg/ml solution for injection"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#EU "EU"
    * jurisdiction = urn:iso:std:iso:3166#EU "EU"
    * language = urn:ietf:bcp:47#en  "en"



RuleSet: 83d27b2c0c103aeb8cf9aa2b77c5f35fListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "halaven"

* status = #current
* mode = #working

* title = "List of all ePIs associated with halaven"

* subject = Reference(mp83d27b2c0c103aeb8cf9aa2b77c5f35f)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#halaven "halaven"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-83d27b2c0c103aeb8cf9aa2b77c5f35f) // halaven en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-83d27b2c0c103aeb8cf9aa2b77c5f35f) // halaven da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-83d27b2c0c103aeb8cf9aa2b77c5f35f
InstanceOf: List

* insert 83d27b2c0c103aeb8cf9aa2b77c5f35fListRuleset
    